Skip to main content
. 2017 Apr 21;429(8):1244–1261. doi: 10.1016/j.jmb.2017.03.014

Table 2.

mAb2 mutations and their binding properties to VEGF

VEGF binder Thermophoresis
KD
(nM)
SPR
KD
(nM)
mAb2_WT 3.7 ± 1.1 4.22
mAb2_SL50K 8.3 ± 1.4 7.88
mAb2_SL50D 4.4 ± 1.3 4.68
mAb2_SL52R 3.2 ± 1.8 2.86
mAb2_VH100R NB NB
mAb2_FH101P NB NB
mAb2_SL50K_SH21R_SH85R 57.1 ± 6.2
mAb2_SL50K_FH101P NB
mAb2_SL50K_SH21R_SH85R_FH101P NB
mAb2_SL52R_FH101P NB
mAb2_SL52R_SH21R_SH85R_FH101P NB
Bevacizumab (Avastin) 4.8 ± 1.6 ~ 1.8–20 [33], [46]

NB: No binding under assay conditions used.

–: Data not gathered.

Comment: Bevacizumab was used for control experiments. The obtained binding affinity is in agreement with currently available published data (KD of ~ 1.8–20 nM; measured by SPR) [33], [46].